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Abstract
Background: Dimebon is a retired non-selective antihistamine drug currently being investigated as a therapeutic
agent for the treatment of Alzheimer’s disease (AD). Results from several completed clinical trials are mixed and
contradictory. Proper interpretations of these clinical observations, as well as future development of dimebon in AD
treatment are complicated by the lack of concrete information on the mechanisms by which dimebon might
benefit AD.
Results: The present studies are designed specifically to assess whether dimebon might modulate b-amyloid
(Ab)-mediated responses which are central to the development and progression of AD dementia. We found that
dimebon is bioavailable in the brains of mice following oral administration. AD mice chronically treated with
dimebon exhibited a trend of improvement in spatial memory function without affecting the levels of total Ab as
well as soluble oligomeric Ab in the brain. The same trend of behavior improvement is also seen in wild type
animals chronically treated with dimebon.
Conclusion: Collectively, our preclinical studies using the TgCRND8 AD mouse model demonstrated that dimebon
might have some beneficial effect in improving cognitive function independent of Alzheimer’s disease-type Ab-
related mechanisms or global energy metabolism in the brain. Observations from our study and others suggesting
dimebon might improve cognition in wild type mice and rats raises the possibility that dimebon might be able to
benefit cognitive function in patients with other neurodegenerative disorders, such as Huntington’s disease, or in
the aging population. Additional studies will be necessary to clarify the mechanisms by which dimebon might
directly or indirectly benefit cognitive function.
Background
The drug latrepirdine (Dimebon
® or Dimebolin) is an
old non-selective antihistamine drug that showed clini-
cal benefits in an eight week, open-label, pilot study
with 14 Alzheimer’s disease (AD) patients in Russia [1].
In a subsequent double-blind, placebo-controlled phase
II clinical trial held in Russia, dimebon significantly
improved and stabilized cognitive function in mild-to-
moderate AD patients over a one-year period [2] and
continued to preserve all key functions when the clinical
trial was extended to a six months open-label extension
or 18 months into the trial. However, in the most
recent multi-national, double-blind, placebo-controlled
confirmatory phase III clinical trials, dimebon failed to
show statistical improvements relative to placebo in cog-
nition and global function in patients with mild-
to-moderate Alzheimer’sd i s e a s e( A D ) .T h i sd r a s t i c
difference was unexpected and very difficult to decipher,
especially in view of the fact that no preclinical informa-
tion on the physiological activities of dimebon on AD-
related mechanisms and phenotypes in vivo are available.
Several dimebon clinical trials are still ongoing,
including a phase III clinical research study (the
CONCERT Study) designed to evaluate whether the
application of dimebon in combination with Aricept
®
(donepezil HCl) can improve cognition and daily living
function in 1050 patients with mild-to-severe AD.
Another ongoing clinical trial is designed to evaluate the
safety and efficacy of dimebon in patients with moder-
ate-to-severe AD receiving existing background therapy
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being developed for treating Huntington’s disease (HD).
An earlier phase II study showed that dimebon treat-
ment led to a modest, but significant improvement in
cognitive functions in HD patients as measured by the
Mini Mental States Exam in HD patients [3]. A multina-
tional phase III Huntington disease trial (the HORIZON
Study) is currently in progress to test the safety and effi-
cacy of dimebon in HD patients.
AD is a multi-faceted disease and understanding the
mechanism(s) of action of any potential treatments is of
great importance. The aggregation of b - amyloid (Ab)
peptides into high molecular weight neurotoxic species
and subsequent formation of amyloid plaques is one of
the two defining neuropathological hallmark of AD.
Most of the current therapeutic strategies are designed
to target Ab by interfering with the synthesis or degra-
dation of Ab, or by interfering with aggregation of Ab
into neurotoxic high molecular weight aggregates. The
present study was designed to evaluate the bioavailability
of dimebon in the brain and to explore the preclinical
efficacy of dimebon in modulating Ab-mediated mec-
hanisms using experimental mouse models of AD. Our
s t u d ym a yp r o v i d ei m p o r t a n ti n f o r m a t i o ni nu n d e r -
standing the results from the clinical trials for dimebon
in AD. Moreover, the current study will also provide
insights for future application of this drug in AD as well
as in HD or other neurological disorders.
Materials and methods
Dimebon
Dimebon was acquired from Ryan Scientific, Inc (Mt.
Pleasant, SC). In initial quality control studies, the 1D
NMR proton spectra of dimebon acquired from Ryan
Scientific, Inc. is comparable to the spectra for dimebon
published by Wu et al. [4]. The purity of the preparation
is 99% (data not shown).
Bioavailability studies
Wild type mice (strain-, age-, gender-matched with
TgCRND8 mice used for preclinical efficacy study
d e s c r i b e db e l o w )w e r eu s e df or dimebon bioavailability
studies. Two months old mice were chronically treated
with 12 mg/kg/day dimebon for 4 months delivered
through their drinking water. On the day of testing,
mice were gavaged with the daily dose of dimebon and
plasma and brain samples were collected at 0, 30, 60,
120 minutes following gavage. Extraction of plasma and
brain tissues was accomplished using the method
described by Nirogi et al. [5] with modification. Briefly,
250 μ L of plasma was extracted with 3.0 mL of hexane:
tetrahydrofuran (THF) (20:80). Samples were vortexed
for 30 s, after which the organic layers were collected.
Samples were extracted a total of 3 times and combined
organic layers were dried under vacuum and analyzed
immediately. Brain tissues (~400 mg) were carefully
weighed, placed in 3.0 mL of phosphate buffered saline
(pH = 7.4) and sonicated to produce a homogenate.
Brain homogenates were then extracted following the
method for plasma described above.
LC-MS analysis of dimebon
Analysis of dimebon in plasma and brain extracts was
accomplished by LC-MS using a system consisting of a
Waters model 2795 separations module equipped with a
ZQ2000 mass selective detector (MSD) (Waters Corp.
Milford, MA). Dried extracts were dissolved in 200 μL
of 20:80 methanol: ddH2Oa n d2 0μLw a si n j e c t e do n t o
the LC-MS system. Dimebon was resolved within 5 min-
utes using a reversed-phase Xterra C18 column (100 ×
2.1 mm i.d.) (Waters Corp, Milford, MA) by isocratic
elution with ddH2O:acetonitrile:formic acid (64.9:35:0.1)
at a flow rate of 0.2 mL/min. Following separation the
c o l u m ne f f l u e n tw a si n t r o d u c e db yp o s i t i v em o d ee l e c -
trospray ionization (ESI) into a Waters ZQ MSD. ESI
capillary voltage was 3.5 kV, and the source and deso-
lvation temperatures were 150°C and 350°C, respectively.
Selected Ion Response (SIR) detection was performed
for m/z 320 with a span of ± 0.50 to detect dimebon.
Chromatographic and spectroscopic data was collected
and analyzed using Empower2 software.
Quantification of dimebon was accomplished using
calibration plots constructed from authentic dimebon
standard reference material (Ryan Scientific). A stock
solution of dimebon was prepared in 20:80 methanol:
ddH2 O at 500 μM. The stock solution was volumetri-
cally diluted in series with methanol:ddH2 O to between
0.01-100 nmol/mL. 20 μL aliquots of these solutions
were injected onto the LC-MS and calibration plots con-
structed by plotting peak area versus dimebon
concentration.
AD mice and treatment
Female TgCRND8 AD transgenic mice expressing
human amyloid precursor protein (APP) containing
Indiana and Swedish double mutation (KM670/671NL+
V717F) were used in the preclinical study. TgCRND8
mice are characterized by an early onset of AD phenotype
including memory impairment at 3-months of age [6].
Both female TgCRND8 mice and WT female littermates
were housed with food and water available ad libitum, and
maintained on a 12:12 h light/dark cycle with lights on at
07:00 h in a temperature-controlled (20 ± 2°C) room prior
to experimental manipulation. All procedures and proto-
cols were approved by the Mount Sinai School of Medi-
cine’s Institutional Animal Care and Use Committee
(IACUC) through the Center for Comparative Medicine
and Surgery. Mice were randomly divided into two groups,
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treated group (dimebon). The treatment started at 2
months of age prior to the onset of AD-type neuropathol-
ogy. At 2 months of age, the amyloid load in TgCRND8
mice is about 100 ng/g tissue forAb1-42and 56 ng/g tissue
forAb1-40 [6]. The animals were treated for 4 months till
the animals reached 6 months of age. In this specific
mouse model of AD, the amyloid neuropathology was
very aggressive and the amyloid content and plaque load
at 6 months of age are equivalent to those found in old
Tg2576 mice [7,8]. Animals were treated with 12 mg/kg/
day dimebon, the dose equivalent to the human dose of 20
mg t.i.d used in the clinical trial using FDA criteria for
converting drug equivalent dosages across species, based
on body surface area ([human equivalent dose in mg/kg =
animal dose in mg/kg × (animal weight in kg/human
weight in kg)
0.33] (http://www.fda.gov)].
Behavioral assessment of cognitive function
by the Morris water maze test
Spatial learning memory was assessed by the Morris
water maze (MWM) behavioral test, as previously
described [9,10]. Mice were tested in a circular pool
filled with water mixed with non-toxic white paint (Dick
Blick Art Materials, IL). In the initial learning phase,
mice were trained for 7 or 8 consecutive days to allow
them to learn to escape from the water onto a hidden/
submerged (1.5 cm below-water surface) escape plat-
form (14 × 14 cm) in a restricted region of the pool
using the spatial cues provided. Spatial learning memory
was assessed by recording the latency time for the ani-
mal to escape from the water onto escape platform as a
function of the number of learning trials during the
learning phase. Twenty-four hours after the last learning
session, mice were subjected to a 45 second probe trial
wherein the escape platform was removed. Spatial mem-
ory retention is reflected by the percentage of time ani-
mals spent within the “target” quadrant of the pool that
previously contained the hidden escape platform. Water
maze activity during training and probe trials was moni-
tored with the Poly-Track video tracking system (San
Diego Instrument).
Assessment of AD-type amyloid neuropathology
Total Ab1-40 or Ab1-42 in the brain were quantified by
sandwich ELISA (Invitrogen, Carlsbad, CA), as pre-
viously described [11]. The level of soluble Ab oligomers
was measured by a commercially available sandwich
ELISA (Invitrogen, Carlsbad, CA) according to the man-
ufacturer’s instruction. Specifically, soluble amyloid pep-
tide was extracted in PBS and centrifuged at 78,500 × g
for 1 h at 4°C, and the supernatant was quantified by
ELISA to specifically detect aggregated Ab [12]. Accord-
ing to the manufacturer, the same monoclonal antibody
specific for the N-terminus of human Ab were used
both as capturing and detecting antibody.
Cell cultures and dimebon treatment
Embryonic-day (E)15 cortico-hippocampal neuronal cul-
tures were prepared from heterozygous TgCRND8
transgenic mice (TgCRND8 neurons) as previously
described [10]. Neurons were treated with different con-
centration of dimebon in triplicate for ~16 hours and con-
ditioned medium was collected for Ab detection using
commercially available kits (Invitrogen, Carlsbad, CA).
In vitro Ab1-42 aggregation assay
Ab1-42 peptides were purchased from American Peptide
(Sunnyvale, CA). Peptides were solublized in 1,1,1,3,3,3,-
hexafluoro-2-propanol (HFI P )f r o mS i g m a ,a n dd r i e d
overnight. Dimebon was dissolved in phosphate buffer
(pH 7.4), mixed with Ab1-42 at 1:1 molar ratio and incu-
bated at 37°C for 24 hours. The effect of dimebon on
Ab aggregation was analyzed by western blot analysis
using 6E10 antibody.
Assays for tricarboxylic acid (TCA) cycle enzymes
activities and protein levels
TgCRND8 mice treated with dimebon or vehicle were
sacrificed and their brains were rapidly dissected. The
brains were frozen at - 80°C till the day of the assays.
The tissue was homogenized in sucrose buffer (0.32 M
sucrose, 0.125 M Tris, 0.1 mM EDTA, 0.6 mM MgCl2,
1 mM DTT, with protease inhibitors, pH 8.0) using Pre-
cellys 24 (Bertin Technologies, Montigny-le-Bretonneux,
France) at 6500 rpm for 8 s. The homogenate was cen-
trifuged, assayed for protein by the method of Bradford
(1976) and immediately used to measure enzyme
activities.
Alpha-ketoglutarate dehydrogenase complex (KGDHC,
oxoglutarate dehydrogenase, EC 1.2.4.2) activity was
measured as per Gibson et al (1988)[13]. The reaction
mixture (200 μl) contained assay buffer (50 mM Tris
pH 7.0, 1 mM MgCl2, 1 mM CaCl2, 0.5 mM K-EDTA,
1 mM dithiothreitol, 1% triton X-100), 0.3 mM thiamine
pyrophosphate, 1 mM NAD, 0.163 mM coenzyme A
and the sample (25-30 μg protein). After the baseline
stabilized at 37°C (about 5 min), 1.25 mM 2-ketogluta-
rate was added to the reaction mixture and the forma-
tion of NADH was monitored for 5 min at 340 nm
using a VERSAmax microplate reader and SoftMax Pro
5.3 software (Molecular Devices, Sunnyvale, CA). The
activity was expressed as nmol NAD
+ oxidized/min/mg
protein (ε340 = 6.23 mM
-1 cm
-1).
The malate dehydrogenase (MDH, EC 1.1.1.37) activ-
ity assay was modified from the method of Rokosh et al
(1973)[14]. For the MDH assay, the 200 μl reaction mix
contained 50 mM sodium glycine buffer, 30 mM malate,
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+, 0.055 mM phenazine
methosulfate, tissue homogenate (3-10 μgp r o t e i n )a n d
0.11 mM 2, 6-dichlorophenolindophenol (DCPIP) Fol-
lowing the baseline reading for 1 min, the reaction was
initiated by adding DCPIP and absorbance was mea-
sured at 600 nm for 1 min at 37°C. The activity
was expressed as nmol DCPIP reduced/min/mg protein
(ε600 = 19.1 mM
-1cm
-1).
Citrate synthase (Citrate oxaloacetate-lyase (CoA-
acetylating), E.C.4.1.3.7) activity was measured using the
citrate synthase assay kit (Sigma-Aldrich, MO, USA) fol-
lowing the manufacturer’si n s t r u c t i o n sw i t h5 - 1 5μgo f
protein in each reaction. The activity was expressed as
nmol 5, 5’-dithiobis (2-nitrobenzoic acid) (DTNB)
reduced/min/mg protein (ε412 = 13.6 mM
-1cm
-1).
The same lysate was used for western blot analysis to
measure the protein levels of these enzymes following
dimebon treatment. Sheep anti-MDH (Rockland Immu-
nochemicals, PA), goat anti-citrate synthase (Santa Cruz,
CA) and goat anti-alpha-KGD (Santa Cruz, CA) were
used to evaluate the levels of these proteins by western
blot analysis and immunoreactive signals were quanti-
fied densitometrically.
Statistical analysis
All values are expressed as mean and standard error of
the mean (SEM). Differences between means were ana-
lyzed using either 1 - way or 2-way repeated measures
ANOVA or 2-tailed Student t test. In all analyses, the
null hypothesis was rejected at the 0.05 level. All statisti-
cal analyses were performed using the Prism Stat pro-
gram (GraphPad Software, Inc., San Diego CA).
Results
Dimebon is bioavailable and can be detected in the
plasma and brain
Bioavailability studies were conducted by measuring
plasma pharmacokinetic response (0-6 h) of dimebon in
mice following chronic dimebon treatment. Following
chronic exposure, we tested plasma pharmacokinetic
response to a single acute dose of dimebon. Six-hour
plasma pharmacokinetic profile of dimebon in mouse
plasma is presented in Figure 1A, left panel. Following
t h eo r a ld o s eo fd i m e b o n ,p l a s m al e v e l so fd i m e b o n
peaked within 30 minutes, reaching a maximum concen-
tration of 202.17 ± 46.14 pmol/mL of plasma. Elimina-
tion of dimebon was rapid as observed by a significant
drop in plasma levels between 30 minutes and 60 min-
utes with levels returning to baseline levels by 6 h fol-
lowing dimebon administration. There are two
additional peaks besides dimebon, which appeared in
the LC-MS separation profile in plasma from dimebon
treated animals, but not from control vehicle gavaged
animals (Figure 1A, right panel), suggesting potential
formation of metabolites. Additional studies are required
to elucidate the potential for dimebon metabolism.
Following plasma pharmacokinetics of dimebon, we
continued to explore whether dimebon might be accu-
mulated in the brain following chronic treatment. As we
have done in our plasma pharmacokinetic studies, mice
were chronically treated with dimebon. Thereafter, mice
were given a single, daily dose of dimebon. Brains were
isolated at different time points extracted and analyzed
by LC-MS as described previously. Similar to our obser-
vations in the plasma, we found dimebon levels in the
brain to peak within 30 minutes following the oral dose
of dimebon, reaching 810.22 pmol/mg brain. Similar to
plasma pharmacokinetics, elimination of dimebon in the
brain was also very rapid and a significant drop was
observed between 30 minutes to 60 minutes with levels
returning to baseline by 6 hours (figure 1B, left panel).
Interestingly, no additional peak was seen in the brain
LC-MS profile, indicating that very likely only dimebon but
no additional metabolites, reaches the brain (Figure 1B,
right panel).
Dimebon may have a positive effect on cognition both in
TgCRND8 and strain-, age-, gender - matched wild type mice
TgCRND8 mice were treated with 12 mg/kg/day
(equivalent to the human dose of 20 mg t.i.d used in the
clinical trial), starting at 8 weeks of age. We found that
4-month dimebon treatment was well-tolerated by
TgCRND8 mice, as reflected by their general health
indexes such as normal food and water intakes, normal
body weight and normal grooming of the mice (data not
shown). One-way ANOVA of escape latencies during 7
days of water maze acquisition revealed that the dime-
bon-treated group improved significantly with each
training session as reflected by a progressive reduction
of escape latency over the 7-day training (Figure 2A,
One-way ANOVA repeated measure; P < 0.0001). The
none-treated control TgCRND8 group did not show sig-
nificant difference during the 7-day training (One-way
ANOVA repeated measure; p = 0.0704). However, the
difference between the two groups did not reach statisti-
cal significance (two-way ANOVA repeated measure;
p > 0.05) (Figure 2A). The dimebon-treated group had a
trend of performing better than the control group dur-
ing the probe trial 24 hours after the last training ses-
sion, which is reflected by both the percentage of time
the mice spent in the target quadrant and by the times
t h em i c ec r o s s e dt h et a r g e tp l a t f o r m( F i g u r e2 Ba n d
2C). However, neither reached statistical significance
(p = 0.078 for platform crossing, p = 0.15 for quadrant
occupation). These results indicate that dimebon treat-
ment might help to consolidate spatial information and
long lasting reference memory in this mouse model
of AD.
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matched wild type mice showed that both treated and
non-treated group showed a significantly reduced latency
during the 7-day training (Figure 2D, one-way ANOVA
repeated measure; P < 0.05 for the non-treated control
group and p < 0.0001 for dimebon-treated group). Both
groups performed well in the probe trial, as reflected by
t h ep e r c e n t a g eo ft i m es p e n ti nt h et a r g e tq u a d r a n tw e l l
above the 25% chance level (Figure 2E). The dimebon-
treated group performed slight better, however, did not
reach statistical significance (p = 0.07).
All groups performed equally well in a visible trial,
excluding the possibility that dimebon treatments might
have affected non-spatial parameters such as sensorimotor
performance and motivation (data not shown) which
might have interfered with the behavioral performance
during the MWM test.
Dimebon treatment has no effect on amyloid
accumulation in the brain of TgCRND8 mice
or in primary neuron culture
Following the MWM behavior test, mice were sacrificed
and brain Ab levels were measured. We did not find
any detectable changes in the content of total amyloid
peptides (Ab1-42 and Ab1-40) in the brain of dimebon
treated mice compared to non-treated control mice, nor
did we find any changes in the level of extracellular high
molecular weight oligomeric Ab species, which are
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Figure 1 Plasma and brain pharmacokinetics of dimebon following acute on chronic dosing in wild type mice.( A )P l a s m a
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cognitive impairments (Figures 3A and 3B), following 4
months of dimebon treatment. There was no change of
plasma levels of Ab1-40 or Ab1-42 in TgCRND8 mice fol-
lowing dimebon treatment (Figure 3C). In parallel stu-
dies, we evaluated the effect of dimebon on APP
processing using primary neuron culture derived from
E15 APP transgenic mice. Consistent with the in vivo
findings, we found that 20-hour treatment of primary
neuron culture with various concentrations of dimebon
does not lead to any significant changes in Ab1-42 and
Ab1-40 contents in the conditioned medium (Figures 3D
and 3E). Moreover, using an in vitro aggregation assay
[15], we found that dimebon did not have any significant
effect on Ab1-42 peptides self-aggregation (Figure 3F).
Collectively, results from our in vitro and in vivo studies
exclude the possibility that APP processing as a direct
target of dimebon.
Dimebon treatment does not affect the activities of key
metabolic enzymes in the brain of TgCRMD8 mice
I tw a sp r e v i o u s l yp r o p o s e dt h a to n eo ft h em e c h a n i s m s
underlying dimebon benefits is its ability to protect/
preserve mitochondrial function in neurons upon beta
amyloid assaults. To evaluate the impact of dimebon
treatment on mitochondrial energy metabolic functions,
we assessed whether long-term dimebon exposure might
modulate citrate synthase, which is the key regulatory
enzyme for the tricarboxylic acid cycle [16]. We found
that dimebon treatment did not change the activity of
citrate synthase in the brain (figure 4A), suggesting that,
contrary to previous assertions, dimebon does not
improve mitochondrial energy metabolism in the brain
of TgCRND8 mice. This is also supported by our obser-
vation that dimebon treatment did not change the level
of citrate synthase protein level in the brain (100 ±
24.7% in control mice vs. 94.2 ± 22.8% in dimebon
Wild type mice
1 2 3 4 5 6 7
0
10
20
30
40
training session
l
a
t
e
n
c
y
 
(
s
e
c
o
n
d
)
0
10
20
30
40
50
0
1
2
3
4
5
p
l
a
t
f
o
r
m
 
c
r
o
s
s
i
n
g
Dimebon
CTRL
Dimebon
CTRL
Dimebon
CTRL
target quadrant
0
10
20
30
40
50
t
a
r
g
e
t
 
q
u
a
d
r
a
n
t
(
%
 
o
f
 
t
i
m
e
)
platform crossing
0
1
2
3
4
5
6
p
l
a
t
f
o
r
m
 
c
r
o
s
s
i
n
g
hidden trial
TgCRND8 mice
Dimebon
CTRL
Dimebon
CTRL
target quadrant platform crossing hidden trial
0
0
10
20
30
40
50
training session
l
a
t
e
n
c
y
 
(
s
e
c
o
n
d
)
1 2 3 4 5 6 7
CTRL
Dimebon
chance level
chance level
A
D
C B
F E
t
a
r
g
e
t
 
q
u
a
d
r
a
n
t
(
%
 
o
f
 
t
i
m
e
)
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also contribute to the regulation of the Tricarboxylic
Acid (TCA) cycle: alpha ketodehydrogenase complex
(a-KGDH) and mitochondrial malate dehydrogenase.
We found no detectable changes in the activity or pro-
tein level of a-KGDH in the brain following dimebon
treatment (Figure 4B). Interestingly, we observed a
~25% reduction in the activity of mitochondrial malate
dehydrogenase in the brain following dimebon treat-
ment (Figure 4C). In view of the fact that citrate
synthase is generally considered to be the key regulatory,
“bottle-neck” enzyme for the TCA cycle, it is not clear
whether the small reduction in mitochondrial malate
dehydrogenase activity might lead to appreciable inhibi-
tion of mitochondrial energy metabolism. Collectively,
our evidence suggests dimebon might not neuroprotect
by improving mitochondrial energy metabolic functions.
Discussion
Alzheimer’s disease is a progressive neurological disor-
der currently affecting 5 million people in the United
States [17]. Its prevalence increases exponentially with
age and poses tremendous burden on public health.
Treatment currently available can only temporarily sta-
bilize or slow the progression of dementia and no effec-
tive cure exists for this devastating disease.
The success of a phase II trials of dimebon with small
cohorts of AD patients brought huge excitement to the
AD community. However, the subsequent failure of a
much larger and better controlled phase III trials has
left us with more questions than answers.
There is no preclinical information on whether dime-
bon might modulate AD related mechanisms or the
basic science underlying its potential function in AD.
Evidence from in vitro studies suggests dimebon might
protect against Ab-mediated toxicity in primary neuron
cultures and might improve mitochondrial function in
cultured cells in the presence or absence of stress
[18-20]. However, it is unclear whether dimebon can
exert disease-modifying activity in vivo and benefit AD
neuropathology and/or clinical symptoms in animal
models of AD.
In this study, we used the TgCRND8 AD mouse
model to investigate the potential role of dimebon on
AD type neuropathology and cognitive deterioration.
TgCRND8 AD mice treated with a dose of dimebon
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exhibited a trend of cognitive function improvement as
reflected by observations from MWM test learning and
probe trials. This marginal improvement in cognitive
behavioral function was also seen in the strain-, age-,
gender matched wild type mice. Our results indicate
that dimebon might influence cognition through
mechanism(s) independent of Ab-mediated neuropathol-
ogy. Evaluation of neuropathology in the brain of dime-
bon treated TgCRND8 mice showed that dimebon had
no effect on contents of total Ab or soluble oligomeric
Ab in the brain, further supporting the argument that
dimebon does not directly target amyloid precursor pro-
tein (APP) processing or Ab oligomerization which has
been proposed to be responsible for cognitive dysfunc-
tion in AD [21-26]. Our in vitro study using primary
neuron culture also confirms that dimebon does not
interfere with APP processing as reflected by the lack of
alteration in the level of extracellular Ab peptides con-
centration in the conditioned medium upon dimebon
treatment. It was recently reported that acute dimebon
treatment increased Ab secretion in Swedish mutant
APP-overexpressing N2a cells [27]. This apparent dis-
crepancy from our studies could be due to the differ-
ences in the drug concentration, cell type and treatment
duration. In vitro aggregation assay also revealed that
dimebon does not directly interfere with Ab aggregation.
Collectively, our studies suggest that APP processing or
Ab oligomerization is not a direct target for the action
of dimebon.
Energy metabolism has been proposed as one of the
potential mechanisms for dimebon’s action. For exam-
ple, in vitro evidence demonstrated dimebon treatment
protects primary neuron cultures against Ab-mediated
neurotoxicity [18,19]. There is also evidence dimebon
protects primary neuron cultures against stress-induced
mitochondrial dysfunction [20]. Nonetheless, recent evi-
dence suggests dimebon-mediated neuroprotection
might be independents of the drug’s potential effects on
energy metabolism. Indeed, Wu et al. [4] demonstrated
dimebon at low concentrations, does not protect against
glutamate-induced neurotoxicity in primary striatal neu-
ronal culture. Consistent with the latter observation, we
found chronic dimebon treatment did not significantly
modulate global energy metabolism in the brain, as
reflected by the lack of alteration in key enzymes activ-
ities, including citrate synthase which is the rate limiting
enzyme in TCA cycle. While an increase in MDH activ-
ity has been reported in AD brains [28], we are yet to
determine whether the decrease we observed in MDH
activity following dimebon treatment is of direct benefi-
cial effect in AD. It is also possible that dimebon might
specifically influence the mitochondial function in select
cell types, such as neurons, glial cells or astrocytes
which were not addressed in this communication since
we did not measure the enzyme activities at cellular
levels.
Our observation that dimebon treatment marginally
improved cognitive behavioral function in wild type
mice suggests that dimebon might modulate cognitive
function via mechanisms independent of Ab-mechan-
ism. Our finding is consistent with previous reports that
dimebon improves cognition in novel object recognition
test and short-term social recognition memory in wild
type rats [1,29,30]. Dimebon is a drug that can interact
with multiple targets with high affinity, including
a-adrenergic receptors, histamine receptors and seroto-
nin receptors [4,29]. It is also possible that the beneficial
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could be due to its inhibition of serotonin 5-HT6 recep-
tors as proposed by Schaffhauser et al [29]. Further
mechanistic studies will be necessary to elucidate the
role of dimebon in cognition.
Conclusion
In conclusion, our preclinical studies demonstrated that
dimebon might have some beneficial effect in improving
cognitive function independent of Alzheimer’s disease-
type Ab-related mechanisms or global energy metabo-
lism in the brain of the TgCRND8 AD mouse model.
Observations from our studies as well as others suggest
dimebon might improve cognition in wild type mice and
rats through Ab-independent mechanisms raise the pos-
sibility that dimebon might be able to benefit cognitive
function in patients with other neurodegenerative disor-
ders, such as HD, or in the aging population. Additional
studies will be necessary to clarify the mechanisms by
which dimebon might directly or indirectly benefit cog-
nitive function.
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